Skip to main content
. Author manuscript; available in PMC: 2015 Mar 1.
Published in final edited form as: Curr Hematol Malig Rep. 2014 Mar;9(1):57–65. doi: 10.1007/s11899-013-0195-9

Table 1.

Phase III trials with hypomethylating agents

Study (ref). Median age, years Hypomethylating agent vs. Comparator Median survival, months Crossover allowed P value
Silverman et al. [36] 68 Azacitidine SQ at 75 mg/m2 ×7d vs. BSC 20 vs. 14 Yes P=0.1
Fenaux et al. [37] 69 Azacitidine SQ at 75 mg/m2 ×7d vs. CCR 24.4 vs. 15 No P<0.001
Lubbert et al. [41] 70 Decitabine 15 mg/m2 IV over 4 hours every 8 hours for 3 days vs. BSC 10.1 vs. 8.5 No P=0.38
Kantarjian et al. [40] 70 Decitabine 15 mg/m2 IV over 3 hours every 8 hours for 3 days vs. BSC 14 vs. 14.9 No P=0.63

BSC: best supportive care

CCR: conventional care regimens (best supportive care, low-dose cytarabine, or intensive chemotherapy as selected by investigators before randomisation)